Compare NextEra Energy, Inc. (NEE) vs Novavax Inc (NVAX) Price & Performance

NextEra Energy (NEE) trades at $83.83, showing modest daily gains of 0.48% amid a bearish technical outlook. The company demonstrates strong fundamentals with $27.4B revenue and 32.4% net margins in 2025, though recent Q4 2025 earnings missed expectations. Positive developments include securing a $1.9B DOE loan for nuclear plant restart and ongoing investor meetings. Analyst consensus remains strongly bullish with a $100.20 price target, representing 20% upside potential from current levels.

NEE presents a compelling long-term investment case with robust profitability and strategic growth initiatives in renewable energy and nuclear power. However, investors face risks from rising debt levels (47.6% debt-to-asset ratio) and recent technical weakness. The stock's current discount to analyst targets offers opportunity, but requires monitoring of execution on growth projects and debt management.

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.